Quarterly report [Sections 13 or 15(d)]

Statements of Cash Flows

v3.26.3
Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash Flows from Operating Activities:    
Net loss $ (2,991) $ (1,383)
Adjustments to reconcile net loss to net cash used in operating activities:    
Issuance of common shares - equity fee on equity offerings to Fortress Biotech 0 395
Stock-based compensation expenses 45 106
Depreciation expense 0 34
Amortization of operating lease right-of-use assets 0 7
Settlement of payables (109) (1,373)
Gain on lease termination 0 (394)
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 62 40
Other receivables 0 435
Accounts payable and accrued expenses 114 (1,202)
Payable and accrued expenses - related party 28 (138)
Lease liabilities 0 (73)
Net cash used in operating activities (2,851) (3,546)
Cash Flows from Investing Activities:    
Proceeds from the sale of property and equipment 0 1,165
Net cash from investing activities 0 1,165
Cash Flows from Financing Activities:    
Proceeds from issuance of common shares, net of offering costs - equity offering 0 6,782
Proceeds from issuance of common shares, net of offering costs - At-the-Market offering (142) 599
Proceeds from warrant exercises 0 7,145
Proceeds from issuance of common shares under ESPP 3 0
Net cash (used in) provided by financing activities (139) 14,526
Net change in cash and cash equivalents (2,990) 12,145
Cash and cash equivalents, beginning of the period 17,266 6,839
Cash and cash equivalents, end of the period 14,276 18,984
Supplemental disclosure of noncash activities:    
Issuance of common shares - Founders Agreement and equity fee to Fortress $ 273 $ 611